SPan-1 and exocrine pancreatic carcinoma. The clinical role of a new tumor marker

International Journal of Biological Markers

Volumn 16, Issue 3, 2001, Pages 189-197

  Frena, A ^a  

^a Ospedale Regionale   (Italy)

Author keywords

CA 19.9; CA 242; CEA; Exocrine pancreatic carcinoma; Lewis gene; Monoclonal antibodies; Pancreatic surgery; SPan 1; TPA; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CA 242 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MONOCLONAL ANTIBODY; SPAN 1 ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CHRONIC PANCREATITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PANCREAS CARCINOMA; PANCREAS DUCT; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELIABILITY; SENSITIVITY AND SPECIFICITY;

EID: 0034765103     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080101600306     Document Type: Article

References (62)

1. Aetiology and epidemiology of pancreatic and periampullary cancer
2. Pancreatic carcinoma - Conclusions and prospects
3. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis
4. Evaluation of cytology and tumor markers of pure pancreatic juice for the diagnosis of pancreatic cancer at early stages
5. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers
6. Immunohistological and immunochemical characterization of a novel pancreatic cancer-associated antigen MUSE11
7. Does serum CAR-3 play a role in pancreatic cancer diagnosis?
8. Blood-group sialyl-Tn antigen is more specific than Tn as a tumor marker in the pancreas
9. Comparison of two sialosyl-Tn binding monoclonal antibodies (MLS102 and B72.3) in detecting pancreatic cancer
10. The protein core of the NCA-related pancreatic adenocarcinoma-associated antigen (DD9-Ag) is NCA-50
11. Tumor antigens CA 195 and CA 19.9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma
12. Characterization of new pancreatic cancer-reactive monoclonal antibodies directed against purified mucin
13. Serological pancreatic tumor markers and the MUC1 apomucin
14. Preparation and partial characterization of a pancreatic cancer-associated glycoprotein expressing CA 50
15. Application of cancer procoagulant as an early detection tumor marker
16. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA 19.9 in the serum and bile of patients with pancreatic and biliary tract diseases: Evaluation of the influence of obstructive jaundice
17. A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA 19.9 and peanut lectin binding assay for the diagnosis of pancreatic cancer
18. Biomechanical and immunological properties of the human carcinoma-associated CAR-3 epitope defined by the monoclonal antibody AR-3
19. Expression of CA 15.3 protein in the cyst contents distinguishes benign from malignant pancreatic mucinous cystic neoplasms
20. Characterization of new monoclonal antibodies directed against normal human exocrine pancreas and pancreatic adenocarcinomas
21. The significance of CD44 in human pancreatic cancer: I. High expression of CD44 in human pancreatic adenocarcinoma
22. CA 19.9: The Italian experience
23. Prognostic value of CA 19-9 serum course in pancreatic cancer
24. CA 19-9 in pancreatic cancer
25. Comparison of CA 19.9 with other tumor markers in the diagnosis of cancer of the pancreas
26. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19.9
27. Clinical utility of the serum CA 19.9 test for diagnosing pancreatic carcinoma in symptomatic patients: A prospective study
28. Comparison of preoperative serum CA 19.9 levels with results of diagnosing imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease
29. CA 19.9 as a screening and diagnostic tool in symptomatic patients: The Japanese experience
30. CA 19.9 as a prognostic index after resection for pancreatic cancer
31. Serum CA 19.9 in the post-surgical follow-up of patients with pancreatic cancer
32. The clinical utility of the CA 19.9 tumor-associated antigen
33. Prognostic values of preoperative and postoperative CEA and CA 19.9 levels in pancreatic cancer
34. Mucin-like antigens in a human pancreatic cell line identified by murine monoclonal antibodies SPan-1 and YPan-1
35. Significance of 2-3 and 2-6 sialylation of Lewis A antigen in pancreas cancer
36. Serum levels of CA 19.9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease
37. Reference values and biological variation for tumor marker CA 19-9 in serum for differenet Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population
38. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA 19.9 antigen
39. Epitope analysis of SPan-1 and DUPAN-2 using synthetized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose
40. Usefulness of a new tumor marker, SPan-1, for the diagnosis of pancreatic cancer
41. History of pancreatic surgery
42. Chemotherapy and radiotherapy in the treatment of pancreatic cancer
43. Advances in the early detection, diagnosis, and staging of pancreatic cancer
44. Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: A prospective study in multiinstitutions
45. The possibility of diagnosing small pancreatic cancer (less than 4 cm) by measuring various serum tumor markers
46. Various tumor markers for small pancreatic cancer with special reference to the present status of pancreatic cancer in Japan and our experience over the past 2 years
47. The value of routine biochemical tests in discriminating between malignant and benign pancreatic tumours
48. A clinical evaluation of monoclonal (CA 19.9, CA 50, CA 12.5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer
49. Wertigkeit der präoperativen diagnostik zur beurteilung der tumorausdehnung bei ductalen pankreascarcinomen
50. High sensitivity and specificity of CA 19.9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings
51. Diagnostic significance of cancer-associated carbohydrate antigen (CA 19.9) concentrations in pancreatic juice: Analysis in pure pancreatic juice collected by endoscopic aspiration and immunohistochemical study in chronic pancreatitis
52. CA 19.9 and carcinoembryonic antigen in pancreatic cancer diagnosis
53. Immunolistochemical localization of CA 19.9 and CEA in pancreatic carcinoma and associated diseases
54. L.A.I. test e markers tumorai (CA 19.9 e TPA). Analisi e prospettive di applicazione nella diagnosi di carcinoima pancreatico
55. Clinical evaluation of a new serum tumor marker CA 242 in pancreatic carcinoma
56. Ductal cancers of the pancreas frequently express markers of gastrointestinal epithelial cells
57. Serum CA 242: The search for a valid marker of pancreatic cancer
58. Carcinoembryonic antigen (CEA) and CEA-related substances in the bile of patients with biliary diseases
59. Factors controlling the circulating CEA levels in pancreatic cancer: Some clinical correlations
60. Pancreatoduodenal carcinoma: A clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA 19.9
61. Usefulness of novel tumour markers
62. Role of tumour markers, cytogenetics